Desensitization of NFκB for overcoming chemoresistance of pancreatic cancer cells to TNF-α or paclitaxel

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 4813-4822

  Fujioka, Shuichi ^a   Son, Kyonsu ^a   Onda, Shinji ^a   Schmidt, Christian ^b   Scrabas, Guido M ^b   Okamoto, Tomoyoshi ^a   Fujita, Tetsuji ^a   Chiao, Paul J ^b   Yanaga, Katsuhiko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemoresistance; Desensitization; Doxycycline; NF B; PANC 1 cells; Pancreatic cancer

Indexed keywords

DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PACLITAXEL; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR P50; TUMOR NECROSIS FACTOR RECEPTOR P55; TUMOR NECROSIS FACTOR RECEPTOR P75; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; DESENSITIZATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; GENE ACTIVATION; GENE ACTIVITY; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UBIQUITINATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA FRAGMENTATION; DOXYCYCLINE; DRUG RESISTANCE, NEOPLASM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME ACTIVATION; HUMANS; NF-KAPPA B; PACLITAXEL; PANCREATIC NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872665123     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Evans DB, Farnell MB, Lillemoe KD, Vollmer C Jr., Strasberg SM and Schulick RD: Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 16: 1736-1744, 2009.
2. Tran KT, Smeenk HG, van Eijck CH, Kazemier G, Hop WC, Greve JW, Terpstra OT, Zijlstra JA, Klinkert P and Jeekel H: Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors. Ann Surg 240: 738-745, 2004.
3. Naugler WE and Karin M: NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 18 : 19-26, 2008.
4. Karin M: Nuclear factor-kappaB in cancer development and progression. Nature 441 : 431-436, 2006.
5. Uetsuka H, Haisa M, Kimura M, Gunduz M, Kaneda Y, Ohkawa T, Takaoka M, Murata T, Nobuhisa T, Yamatsuji T, Matsuoka J, Tanaka N and Naomoto Y: Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Experimental cell research 289 : 27-35, 2003.
6. Yeh PY, Chuang SE, Yeh KH, Song YC and Cheng AL: Involvement of nuclear transcription factor-kappa B in low-dose doxorubicin-induced drug resistance of cervical carcinoma cells. Biochemical pharmacology 66 : 25-33, 2003.
7. Mujtaba T and Dou QP: Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discovery medicine 12: 471-480, 2011.
8. Wong HR, Ryan M and Wispe JR: Stress response decreases NF-kappaB nuclear translocation and increases I-kappaBalpha expression in A549 cells. The Journal of clinical investigation 99 : 2423-2428, 1997.
9. Raju U, Lu R, Noel F, Gumin GJ and Tofilon PJ: Failure of a second X-ray dose to activate nuclear factor kappaB in normal rat astrocytes. J Biol Chem 272 : 24624-24630, 1997.
10. Fujioka S, Schmidt C, Sclabas GM, Li Z, Pelicano H, Peng B, Yao A, Niu J, Zhang W, Evans DB, Abbruzzese JL, Huang P and Chiao PJ: Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB. J Biol Chem 279: 27549-27559, 2004.
11. Chiao PJ, Miyamoto S and Verma IM: Autoregulation of I kappa B alpha activity. Proc Natl Acad Sci USA 91: 28-32,1994.
12. Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, Tsao MS, Evans DB, Abbruzzese JL, McDonnell TJ and Chiao PJ: The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 21 : 6510-6519, 2002.
13. Wang CY, Cusack JC Jr., Liu R and Baldwin AS Jr.: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5: 412-417, 1999.
14. Wang CY, Mayo MW and Baldwin AS, Jr.: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NFkappaB. Science 274: 784-787, 1996.
15. Zandi E, Rothwarf DM, Delhase M, Hayakawa M and Karin M: The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 91: 243-252, 1997.
16. Safran H, Moore T, Iannitti D, Dipetrillo T, Akerman P, Cioffi W, Harrington D, Quirk D, Rathore R, Cruff D, Vakharia J, Vora S, Savarese D and Wanebo H: Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 49: 1275-1279, 2001.
17. Graziano F and Cascinu S: Docetaxel chemotherapy for pancreatic cancer: Do results support certainty? Italian Group for the Study of Gastrointestinal Tract Carcinomas. J Clin Oncol 18: 445-446, 2000.
18. Androulakis N, Kourousis C, Dimopoulos MA, Samelis G, Kakolyris S, Tsavaris N, Genatas K, Aravantinos G, Papadimitriou C, Karabekios S, Stathopoulos GP and Georgoulias V: Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J Clin Oncol 17: 1779-1785, 1999.
19. Son K, Fujioka S, Iida T, Furukawa K, Fujita T, Yamada H, Chiao PJ and Yanaga K: Doxycycline induces apoptosis in PANC-1 pancreatic cancer cells. Anticancer Res 29: 3995-4003, 2009.
20. Hirota K, Murata M, Itoh T, Yodoi J and Fukuda K: Redox-sensitive transactivation of epidermal growth factor receptor by tumor necrosis factor confers the NF-kappa B activation. J Biol Chem 276 : 25953-25958, 2001.
21. Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S, Gelfanov V, Boswell SH, Goulet RJ, Jr., Sledge GW, Jr. and Nakshatri H: Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 19: 4159-4169, 2000.
22. Duan Z, Feller AJ, Penson RT, Chabner BA and Seiden MV: Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 5 : 3445-3453, 1999.
23. Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK and Cheng AL: Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. Biochemical pharmacology 63: 1423-1430, 2002.
24. Haas JG, Baeuerle PA, Riethmuller G and Ziegler-Heitbrock HW: Molecular mechanisms in down-regulation of tumor necrosis factor expression. Proc Natl Acad Sci USA 87 : 9563-9567, 1990.
25. Supakar PC, Jung MH, Song CS, Chatterjee B and Roy AK: Nuclear factor kappa B functions as a negative regulator for the rat androgen receptor gene and NF-kappa B activity increases during the age-dependent desensitization of the liver. J Biol Chem 270: 837-842, 1995.
26. Zuckerman SH and Evans GF: Endotoxin tolerance: in vivo regulation of tumor necrosis factor and interleukin-1 synthesis is at the transcriptional level. Cellular immunology 140 : 513-519, 1992.
27. Fujihara M, Wakamoto S, Ito T, Muroi M, Suzuki T, Ikeda H and Ikebuchi K: Lipopolysaccharide-triggered desensitization of TNF-alpha mRNA expression involves lack of phosphorylation of IkappaBalpha in a murine macrophage-like cell line, P388D1. Journal of leukocyte biology 68: 267-276, 2000.
28. Lee M and Jeon YJ: Paclitaxel-induced immune suppression is associated with NF-kappaB activation via conventional PKC isotypes in lipopolysaccharide- stimulated 70Z/3 pre-B lymphocyte tumor cells. Mol Pharmacol 59: 248-253, 2001.
29. Ziegler-Heitbrock L: The p50-homodimer mechanism in tolerance to LPS. J Endotoxin Res 7: 219-222, 2001.
30. Lei W, Mayotte JE and Levitt ML: Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells. Anticancer Res 19: 221-228, 1999.
31. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG and Korc M: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13: 565-569, 1993.
32. Habib AA, Chatterjee S, Park SK, Ratan RR, Lefebvre S and Vartanian T: The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NFkappaB)-inducing kinase to activate NF-kappa B. Identification of a novel receptor-tyrosine kinase signalosome. J Biol Chem 276: 8865-8874, 2001.
33. Bohuslav J, Kravchenko VV, Parry GC, Erlich JH, Gerondakis S, Mackman N and Ulevitch RJ: Regulation of an essential innate immune response by the p50 subunit of NF-kappaB. The Journal of clinical investigation 102: 1645-1652, 1998.
34. Harhaj EW and Sun SC: Regulation of RelA subcellular localization by a putative nuclear export signal and p50. Mol Cell Biol 19: 7088-7095, 1999.